Last reviewed 2026-05-19 · How we verify

Ketorolac Ophthalmic Solution

Ketorolac Ophthalmic Solution is a Nonsteroidal anti-inflammatory drug (NSAID) Small molecule drug developed by Bausch & Lomb Incorporated. It is currently FDA-approved for Postoperative ocular pain and inflammation following cataract surgery, Allergic conjunctivitis, Ocular pain and photophobia associated with corneal abrasion or refractive surgery.

Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.

Ketorolac Ophthalmic Solution is a small molecule medication used to treat various eye conditions, including Cataract, Wet Macular Degeneration, Open Angle Glaucoma, Miosis, and Dry Eye. It is administered as a 0.4% solution, although its exact mechanism of action is not specified in the provided information.

At a glance

Mechanism of action

As a topical ophthalmic NSAID, ketorolac blocks COX-1 and COX-2 enzymes in ocular tissues, thereby decreasing production of inflammatory prostaglandins. This reduces ocular pain, inflammation, and swelling. When applied topically to the eye, it provides local anti-inflammatory and analgesic effects without significant systemic absorption.

Approved indications

• Postoperative ocular pain and inflammation following cataract surgery
• Allergic conjunctivitis
• Ocular pain and photophobia associated with corneal abrasion or refractive surgery

Common side effects

• Ocular irritation or stinging
• Conjunctival hyperemia
• Headache
• Corneal erosion or ulceration (rare)

Key clinical trials

• INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study (PHASE1)
• Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population (PHASE4)
• Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC (PHASE1, PHASE2)
• Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
• Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults (PHASE2)
• Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3% (EARLY_PHASE1)
• Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT (PHASE4)
• Efficacy Study of Ketorolac and HPMC to Treat Dry Eye (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Ketorolac Ophthalmic Solution CI brief — competitive landscape report
• Ketorolac Ophthalmic Solution updates RSS · CI watch RSS
• Bausch & Lomb Incorporated portfolio CI

Frequently asked questions about Ketorolac Ophthalmic Solution

Related

• Drug class: All Nonsteroidal anti-inflammatory drug (NSAID) drugs
• Target: All drugs targeting Cyclooxygenase (COX-1 and COX-2)
• Manufacturer: Bausch & Lomb Incorporated — full pipeline
• Therapeutic area: All drugs in Ophthalmology
• Indication: Drugs for Postoperative ocular pain and inflammation following cataract surgery
• Indication: Drugs for Allergic conjunctivitis
• Indication: Drugs for Ocular pain and photophobia associated with corneal abrasion or refractive surgery

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing